Acadian Asset Management LLC Has $7.14 Million Stock Position in Inogen, Inc $INGN

Acadian Asset Management LLC lessened its holdings in Inogen, Inc (NASDAQ:INGN) by 1.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,017,241 shares of the medical technology company’s stock after selling 11,081 shares during the quarter. Acadian Asset Management LLC owned 3.78% of Inogen worth $7,144,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of INGN. CWM LLC lifted its position in shares of Inogen by 11.0% during the 2nd quarter. CWM LLC now owns 16,258 shares of the medical technology company’s stock worth $114,000 after buying an additional 1,611 shares during the last quarter. Cubist Systematic Strategies LLC raised its stake in Inogen by 1.4% during the first quarter. Cubist Systematic Strategies LLC now owns 124,993 shares of the medical technology company’s stock worth $891,000 after acquiring an additional 1,751 shares in the last quarter. American Century Companies Inc. lifted its holdings in shares of Inogen by 6.4% in the first quarter. American Century Companies Inc. now owns 58,380 shares of the medical technology company’s stock worth $416,000 after acquiring an additional 3,524 shares during the last quarter. Deutsche Bank AG lifted its holdings in shares of Inogen by 61.6% in the first quarter. Deutsche Bank AG now owns 14,856 shares of the medical technology company’s stock worth $106,000 after acquiring an additional 5,664 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC boosted its stake in shares of Inogen by 44.9% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 20,078 shares of the medical technology company’s stock valued at $150,000 after purchasing an additional 6,220 shares in the last quarter. Institutional investors own 89.94% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Inogen in a research report on Tuesday. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $11.00.

Inogen Price Performance

Shares of NASDAQ INGN opened at $7.09 on Thursday. The company has a 50 day simple moving average of $8.28 and a 200 day simple moving average of $7.35. Inogen, Inc has a 1 year low of $5.70 and a 1 year high of $12.91. The firm has a market cap of $192.49 million, a PE ratio of -7.02 and a beta of 1.83.

Inogen (NASDAQ:INGN) last posted its earnings results on Wednesday, November 5th. The medical technology company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. The firm had revenue of $92.39 million for the quarter, compared to analyst estimates of $92.20 million. Inogen had a negative net margin of 7.31% and a negative return on equity of 13.21%. Inogen has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, research analysts anticipate that Inogen, Inc will post -1.73 earnings per share for the current fiscal year.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.